Verrica Pharmaceuticals Inc.
NASDAQ:VRCABiotechnology
Healthcare
$3.14 -0.26%
-$0.02 today
- Market cap
- $53.94M
- Beta
- 1.49
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$1.67
52W Low $3.28High $9.82
Volume 0.10M
Average 0.08M
Income Statement
Follow revenue through to earnings.
Revenue
$35.58M
FY 2025 · Annual
+370.2% YoYOperating Income
-$11.94M
FY 2025 · Annual
Net Income
-$17.89M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12M | 9.03M | 5.12M | 7.57M | 35.58M |
| Cost of Revenue | 472K | 725K | 746K | 2.74M | 3.44M |
| Gross Profit | 11.53M | 8.31M | 4.38M | 4.83M | 32.14M |
| Gross Margin | 96.1% | 92.0% | 85.4% | 63.8% | 90.3% |
| Research & Development | 15.93M | 12.2M | 20.3M | 11.84M | 8.86M |
| Selling, General & Admin | 26.98M | 17.41M | 47.31M | 58.82M | 35.22M |
| Operating Expenses | 42.44M | 29.6M | 70.14M | 70.75M | 44.08M |
| Depreciation & Amortization | 472K | 718K | 836K | 1.27M | 781K |
| EBITDA | (30.31M) | (21.6M) | (62.2M) | (65.9M) | (9.36M) |
| EBITDA Margin | -252.6% | -239.1% | -1213.8% | -871.0% | -26.3% |
| Operating Income | (30.91M) | (21.3M) | (65.76M) | (65.92M) | (11.94M) |
| Operating Margin | -257.6% | -235.8% | -1283.4% | -871.3% | -33.6% |
| Interest Income | 123K | 476K | 2.74M | 1.42M | 929K |
| Interest Expense | 4.3M | 2.17M | 3.96M | 9.41M | 7.74M |
| Other Income / Expenses | (4.17M) | (3.19M) | (1.24M) | (10.66M) | (5.95M) |
| Income Before Tax | (35.08M) | (24.49M) | (67M) | (76.58M) | (17.89M) |
| Pre-Tax Margin | -292.3% | -271.1% | -1307.5% | -1012.1% | -50.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.08M) | (24.49M) | (67M) | (76.58M) | (17.89M) |
| Net Margin | -292.3% | -271.1% | -1307.5% | -1012.1% | -50.3% |
| EPS (Basic) | (12.97) | (7.17) | (14.78) | (14.78) | (1.68) |
| EPS (Diluted) | (12.97) | (7.17) | (14.78) | (14.78) | (1.68) |
| 2.7M | 3.42M | 4.53M | 5.18M | 10.65M | |
| 2.7M | 3.42M | 4.53M | 5.18M | 10.65M |
VRCA Earnings Waterfall · TTM
NASDAQ:VRCA · Revenue to Net Income
Key Ratios
EPS$-1.56
Gross Margin85.8%
Net Margin-87.9%
P/E Ratio5.0
P/S Ratio8.9
Analysis
$37.2M of revenue converted into -$17.8M of net income for the selected period. Gross margin is 85.8% and net margin is -87.9%, showing how much revenue survives after costs and taxes. EPS is $-1.56, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 |
How much revenue does VRCA generate?
Verrica Pharmaceuticals Inc. (VRCA) reported $35.58M of revenue in fiscal 2025.
Is VRCA profitable?
Verrica Pharmaceuticals Inc. (VRCA) reported -$17.89M of net income, with a net margin of -50.3%.
Continue the stock analysis
Jump to another research area for this company.